Details for Patent: 9,763,880
✉ Email this page to a colleague
Which drugs does patent 9,763,880 protect, and when does it expire?
Patent 9,763,880 protects DOCETAXEL and is included in one NDA.
This patent has twenty-six patent family members in twenty-one countries.
Summary for Patent: 9,763,880
Title: | Non-aqueous taxane formulations and methods of using the same |
Abstract: | Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations. |
Inventor(s): | Nabeta; Kiichiro (Tokyo, JP) |
Assignee: | Teikoku Pharma USA, Inc. (San Jose, CA) |
Application Number: | 15/066,087 |
Patent Claim Types: see list of patent claims | Use; Formulation; |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 9,763,880
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-001 | Dec 22, 2015 | AP | RX | Yes | Yes | 9,763,880 | ⤷ Subscribe | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY | ⤷ Subscribe | |||
Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-001 | Dec 22, 2015 | AP | RX | Yes | Yes | 9,763,880 | ⤷ Subscribe | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL | ⤷ Subscribe | |||
Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-001 | Dec 22, 2015 | AP | RX | Yes | Yes | 9,763,880 | ⤷ Subscribe | USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER | ⤷ Subscribe | |||
Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-001 | Dec 22, 2015 | AP | RX | Yes | Yes | 9,763,880 | ⤷ Subscribe | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY | ⤷ Subscribe | |||
Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-001 | Dec 22, 2015 | AP | RX | Yes | Yes | 9,763,880 | ⤷ Subscribe | TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,763,880
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 092759 | ⤷ Subscribe | |||
Australia | 2013327563 | ⤷ Subscribe | |||
Brazil | 112015006692 | ⤷ Subscribe | |||
Canada | 2885930 | ⤷ Subscribe | |||
China | 104822262 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |